Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA3 | P07451 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878246 | 1.00 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL21313417 | 1.00 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3789749 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1880935 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3789746 | 0.87 | LMNA (0.69) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13911898 | 0.86 | LMNA (0.71) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL28230116 | 0.84 | LMNA (0.78) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4445759 | 0.83 | LMNA (0.63) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11556911 | 0.82 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13788510 | 0.81 | LMNA (0.75) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11085059-B2 | Methylopila sp. and use thereof in selective resolution preparation of (S)-α-ethyl-2-oxo-1-pyrrolidineacetate | CHANGXING PHARMACEUTICAL CO. LTD. (CN) | 2021-08-10 | — | — | US | claimed |
| EP-3533862-B1 | METHYLOPILA SP. AND USE THEREOF IN SELECTIVE RESOLUTION AND PREPARATION OF (S)-ALPHA-ETHYL-2-OXO-1 -PYRROLIDINE ACETATE | Changxing pharmaceutical co ltd (CN) | 2021-04-28 | — | — | EP | claimed |
| EP-3533862-A1 | METHYLOCYSTIS AND USE THEREOF IN SELECTIVE RESOLUTION AND PREPARATION OF (S)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINE ACETATE | Changxing Pharmaceutical Co. Ltd. (CN) | 2019-09-04 | — | — | EP | claimed |
| CN-110799494-B | Method for preparing levetiracetam without solvent | 浙江华海药业股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-115734964-A | Preparation method of levetiracetam intermediate | 浙江华海药业股份有限公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-110799495-B | Synthesis method of levetiracetam | 浙江华海药业股份有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-11085059-B2 | Methylopila sp. and use thereof in selective resolution preparation of (S)-α-ethyl-2-oxo-1-pyrrolidineacetate | CHANGXING PHARMACEUTICAL CO. LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-11085059-B2 | Methylopila sp. and use thereof in selective resolution preparation of (S)-α-ethyl-2-oxo-1-pyrrolidineacetate | CHANGXING PHARMACEUTICAL CO. LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| EP-3533862-B1 | METHYLOPILA SP. AND USE THEREOF IN SELECTIVE RESOLUTION AND PREPARATION OF (S)-ALPHA-ETHYL-2-OXO-1 -PYRROLIDINE ACETATE | Changxing pharmaceutical co ltd (CN) | 2021-04-28 | — | — | EP | disclosed |
| EP-3533862-A1 | METHYLOCYSTIS AND USE THEREOF IN SELECTIVE RESOLUTION AND PREPARATION OF (S)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINE ACETATE | Changxing Pharmaceutical Co. Ltd. (CN) | 2019-09-04 | — | — | EP | disclosed |
| EP-3533862-A1 | METHYLOCYSTIS AND USE THEREOF IN SELECTIVE RESOLUTION AND PREPARATION OF (S)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINE ACETATE | Changxing Pharmaceutical Co. Ltd. (CN) | 2019-09-04 | — | — | EP | disclosed |
| US-7563912-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2009-07-21 | — | — | US | disclosed |
| US-7563912-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1419144-B1 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB PHARMA SA (BE) | 2008-10-08 | — | — | EP | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| WO-2003014080-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2D6, OTC, CYP2B6 | LMNA 2327/4885CA12 2417/4885CA1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.